Tau post-translational modifications in wildtype and human amyloid precursor protein transgenic mice

The microtubule-associated protein tau has been implicated in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders. Reducing tau levels ameliorates AD-related synaptic, network, and behavioral abnormalities in transgenic mice expressing human amyloid precursor protein (hAPP). We used mass spectrometry to characterize the post-translational modification of endogenous tau isolated from wild-type and hAPP mice. We identified seven types of tau modifications at 63 sites in wild-type mice. Wild-type and hAPP mice had similar modifications, supporting the hypothesis that neuronal dysfunction in hAPP mice is enabled by physiological forms of tau. Our findings provide clear evidence for acetylation and ubiquitination of the same lysine residues; some sites were also targeted by lysine methylation. Our findings refute the hypothesis of extensive O-linked N-acetylglucosamine (O-GlcNAc) modification of endogenous tau. The complex post-translational modification of physiological tau suggests that tau is regulated by diverse mechanisms.

[1]  M. Goedert,et al.  Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. , 1990, The EMBO journal.

[2]  Khadija Iqbal,et al.  Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. , 1993, The Journal of biological chemistry.

[3]  E. Mandelkow,et al.  Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding , 1993, Neuron.

[4]  Yasuo Ihara,et al.  Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments , 1993, Neuron.

[5]  G. Drewes,et al.  Tau domains, phosphorylation, and interactions with microtubules , 1995, Neurobiology of Aging.

[6]  R. Brandt,et al.  Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain , 1995, The Journal of cell biology.

[7]  G. Hart,et al.  The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine* , 1996, The Journal of Biological Chemistry.

[8]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Mandelkow,et al.  The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. , 1999, Molecular biology of the cell.

[10]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[11]  E. Mandelkow,et al.  Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  E. Mandelkow,et al.  Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure* , 2001, The Journal of Biological Chemistry.

[13]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[14]  Jia-Jia Liu,et al.  Microtubule-associated protein 1B , 2002, The Journal of cell biology.

[15]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Burlingame,et al.  Phosphorylation state of postsynaptic density proteins , 2005, Journal of neurochemistry.

[17]  M. Mann,et al.  Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.

[18]  Jonathan C Trinidad,et al.  O-Linked N-Acetylglucosamine Proteomics of Postsynaptic Density Preparations Using Lectin Weak Affinity Chromatography and Mass Spectrometry*S , 2006, Molecular & Cellular Proteomics.

[19]  Stefani N. Thomas,et al.  Alzheimer Disease-specific Conformation of Hyperphosphorylated Paired Helical Filament-Tau Is Polyubiquitinated through Lys-48, Lys-11, and Lys-6 Ubiquitin Conjugation* , 2006, Journal of Biological Chemistry.

[20]  Alma L. Burlingame,et al.  Comprehensive Identification of Phosphorylation Sites in Postsynaptic Density Preparations*S , 2006, Molecular & Cellular Proteomics.

[21]  Steven P Gygi,et al.  A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.

[22]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[23]  Kit-Yi Leung,et al.  Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis* , 2007, Journal of Biological Chemistry.

[24]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[25]  R. Nelson,et al.  Anesthesia Leads to Tau Hyperphosphorylation through Inhibition of Phosphatase Activity by Hypothermia , 2007, The Journal of Neuroscience.

[26]  M. Novák,et al.  High-yield purification of fetal tau preserving its structure and phosphorylation pattern. , 2008, Journal of immunological methods.

[27]  Peter R Baker,et al.  In-depth Analysis of Tandem Mass Spectrometry Data from Disparate Instrument Types*S , 2008, Molecular & Cellular Proteomics.

[28]  M. Zvelebil,et al.  Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase Cγ1, Grb2, and Src Family Kinases* , 2008, Journal of Biological Chemistry.

[29]  G. Schellenberg,et al.  Tau isoform regulation is region‐ and cell‐specific in mouse brain , 2008, The Journal of comparative neurology.

[30]  G. Davies,et al.  A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. , 2008, Nature chemical biology.

[31]  E. Seto,et al.  Lysine acetylation: codified crosstalk with other posttranslational modifications. , 2008, Molecular cell.

[32]  Robert J Chalkley,et al.  Identification of protein O-GlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides , 2009, Proceedings of the National Academy of Sciences.

[33]  L. Schiapparelli,et al.  Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels , 2009, Neurobiology of Disease.

[34]  Jianhua Shi,et al.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[35]  J. Shabanowitz,et al.  Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/Enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry* , 2009, Molecular & Cellular Proteomics.

[36]  Electrical Coupling between Olfactory Glomeruli , 2010, Neuron.

[37]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[38]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[39]  L. Buée,et al.  Nuclear Tau, a Key Player in Neuronal DNA Protection* , 2010, The Journal of Biological Chemistry.

[40]  Robert J Chalkley,et al.  Protein PTMs: post-translational modifications or pesky trouble makers? , 2010, Journal of mass spectrometry : JMS.

[41]  D. Vocadlo,et al.  Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody , 2011, Amino Acids.

[42]  V. Haroutunian,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[43]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[44]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[45]  Stefani N. Thomas,et al.  Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach , 2011, Acta Neuropathologica.

[46]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[47]  H. Pant,et al.  Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  Peter R Baker,et al.  Modification Site Localization Scoring Integrated into a Search Engine* , 2011, Molecular & Cellular Proteomics.

[49]  S. Guan,et al.  A Data Processing Pipeline for Mammalian Proteome Dynamics Studies Using Stable Isotope Metabolic Labeling* , 2011, Molecular & Cellular Proteomics.

[50]  J. Trojanowski,et al.  The acetylation of tau inhibits its function and promotes pathological tau aggregation. , 2011, Nature communications.

[51]  Matthew S Macauley,et al.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. , 2012, Nature chemical biology.

[52]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[53]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[54]  A. Burlingame,et al.  Global Identification and Characterization of Both O-GlcNAcylation and Phosphorylation at the Murine Synapse* , 2012, Molecular & Cellular Proteomics.

[55]  G. Lippens,et al.  Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice , 2013, PloS one.

[56]  Meaghan Morris,et al.  Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice , 2013, Neurobiology of Aging.

[57]  G. Bloom,et al.  Amyloid-&bgr; signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease , 2013, Journal of Cell Science.

[58]  E. Mandelkow,et al.  Amyloid‐β oligomers induce synaptic damage via Tau‐dependent microtubule severing by TTLL6 and spastin , 2013, The EMBO journal.

[59]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[60]  Anatol C. Kreitzer,et al.  Physiological Brain Activity Causes DNA Double Strand Breaks in Neurons — Exacerbation by Amyloid-β , 2013, Nature Neuroscience.

[61]  S. Younkin,et al.  Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy , 2013, The Journal of Neuroscience.

[62]  C. Troakes,et al.  Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease* , 2013, The Journal of Biological Chemistry.

[63]  Ailan Guo,et al.  Immunoaffinity Enrichment and Mass Spectrometry Analysis of Protein Methylation , 2013, Molecular & Cellular Proteomics.

[64]  Casey Cook,et al.  Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance , 2013, Human molecular genetics.

[65]  E. Roberson,et al.  Seizure resistance without parkinsonism in aged mice after tau reduction , 2014, Neurobiology of Aging.

[66]  L. Mucke,et al.  Tau Reduction Prevents Disease in a Mouse Model of Dravet Syndrome , 2014, Annals of neurology.

[67]  Stefani N. Thomas,et al.  Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. , 2014, The Biochemical journal.

[68]  Keith A. Vossel,et al.  Tau reduction prevents A-induced axonal transport deficits by blocking activation of GSK 3 , 2015 .

[69]  S. Li,et al.  Non-histone protein methylation as a regulator of cellular signalling and function , 2014, Nature Reviews Molecular Cell Biology.